Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H26N4O23P4 |
Molecular Weight | 790.3071 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N3C=CC(=O)NC3=O)N4C=CC(=O)NC4=O
InChI
InChIKey=NMLMACJWHPHKGR-NCOIDOBVSA-N
InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
Molecular Formula | C18H26N4O23P4 |
Molecular Weight | 790.3071 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18600475Curator's Comment: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600475
Curator's Comment: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/
Diquafosol, a dinucleotide Up4U, is an agonist for purinergic P2Y2 receptor. Diquafosol stimulated water and mucin secretion by acting on P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations. The Japanese Ministry of Health, Labour and Welfare granted approval for DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) for the treatment of dry eye.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4398 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600475 |
0.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DIQUAS Approved UseDIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium) should be used in patients diagnosed with dry eye, associated with keratoconjunctival epithelium disorders that accompany lacrimal fluid abnormality. Launch Date2010 |
PubMed
Title | Date | PubMed |
---|---|---|
Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. | 2001 Apr |
|
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. | 2001 Aug |
|
Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. | 2001 Jan |
|
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. | 2001 Jan 22 |
|
Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits. | 2002 |
|
Diquafosol tetrasodium: a novel dry eye therapy. | 2004 Jan |
|
Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. | 2004 Nov |
|
Recent advances in the management of ocular complications of Sjögren's syndrome. | 2005 Jul |
|
P2 receptors activated by uracil nucleotides--an update. | 2006 |
|
New approaches in Sjögren's syndrome therapy. | 2007 Mar |
|
[A molecular marker for dry eye]. | 2007 Mar |
|
Therapeutic targets in dry eye syndrome. | 2008 Apr |
|
Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. | 2008 Aug |
|
Preliminary effects of oral uridine on the ocular surface in dry eye patients. | 2009 Aug |
Sample Use Guides
DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium). Usually, instill 1 drop a time 6 times daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28280412/
3% diquafosol tetrasodium had a significant, time-dependent, inhibitory effect on human corneal epithelial cells (HCEC) proliferation and cytotoxicity. HCECs treated with diquafosol detached more from the bottoms of dishes and damaged cells showed degenerative changes, such as, reduced numbers of microvilli, vacuole formation, and chromatin of the nuclear remnant condensed along the nuclear periphery.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:59:21 GMT 2023
by
admin
on
Sat Dec 16 15:59:21 GMT 2023
|
Record UNII |
7828VC80FJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78283
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40208689
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
C403315
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
59985-21-6
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
SUB87041
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL221326
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
7828VC80FJ
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
4900
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
100000139278
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
148197
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
m4661
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
8326
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
C65436
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
27791
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
DIQUAFOSOL
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|